Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits...

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Retinoic acid receptor-related orphan receptor gamma (RORγ) is a critical transcription factor in autoimmune disease pathogenesis.
• RORγ regulates the production of pro-inflammatory cytokines, notably IL-17, which are central to autoimmune conditions.
• Small molecule inhibitors of RORγ have emerged as a significant therapeutic strategy for autoimmune diseases.

Purpose of the Study:

• To review and summarize the RORγ inhibitors that have been disclosed in scientific literature.
• To discuss the therapeutic progress and potential of these RORγ inhibitors in managing autoimmune diseases.
• To highlight the evolving landscape of RORγ-targeted therapies for inflammatory and autoimmune conditions.

Main Methods:

• Literature review of disclosed RORγ inhibitors.
• Analysis of preclinical and clinical data for RORγ inhibitor efficacy.
• Discussion of the role of IL-17 in autoimmune diseases and RORγ inhibition.

Main Results:

• Several small molecule RORγ inhibitors have been developed and are progressing.
• Clinical proof-of-concept for RORγ inhibition in psoriasis has been established with VTP-43742.
• Multiple RORγ inhibitors are now undergoing clinical trials for autoimmune disease interventions.

Conclusions:

• RORγ inhibitors represent a promising therapeutic avenue for autoimmune diseases.
• The development of RORγ inhibitors is rapidly advancing, with several candidates in clinical trials.
• Targeting RORγ offers a potential strategy to modulate IL-17-mediated inflammation in autoimmune conditions.